MRNA Stock - Moderna, Inc.
Unlock GoAI Insights for MRNA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.20B | $6.85B | $18.88B | $17.74B | $803.39M |
| Gross Profit | $1.74B | $2.15B | $13.46B | $15.12B | $764.21M |
| Gross Margin | 54.2% | 31.5% | 71.3% | 85.2% | 95.1% |
| Operating Income | $-3,945,000,000 | $-4,239,000,000 | $9.42B | $13.30B | $-763,144,000 |
| Net Income | $-3,561,000,000 | $-4,714,000,000 | $8.36B | $12.20B | $-747,064,000 |
| Net Margin | -111.3% | -68.8% | 44.3% | 68.8% | -93.0% |
| EPS | $-9.27 | $-12.34 | $21.26 | $30.31 | $-1.96 |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteEarnings History & Surprises
MRNAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 13, 2026 | $-2.79 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.87 | $-0.51 | +72.7% | ✓ BEAT |
Q3 2025 | Aug 1, 2025 | $-2.99 | $-2.13 | +28.8% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-2.92 | $-2.52 | +13.7% | ✓ BEAT |
Q1 2025 | Feb 14, 2025 | $-2.68 | $-2.50 | +6.7% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-1.91 | $0.03 | +101.6% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-3.35 | $-3.33 | +0.6% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-3.56 | $-3.07 | +13.8% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.97 | $0.55 | +156.7% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-2.01 | $-1.39 | +30.8% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-3.84 | $-3.62 | +5.7% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-1.77 | $0.19 | +110.7% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $4.68 | $3.61 | -22.9% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $3.29 | $2.53 | -23.1% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $4.55 | $5.24 | +15.2% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $5.21 | $8.58 | +64.7% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $9.90 | $11.29 | +14.0% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $9.05 | $7.70 | -14.9% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $5.96 | $6.46 | +8.4% | ✓ BEAT |
Latest News
Frequently Asked Questions about MRNA
What is MRNA's current stock price?
What is the analyst price target for MRNA?
What sector is Moderna, Inc. in?
What is MRNA's market cap?
Does MRNA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MRNA for comparison